Literature DB >> 19906441

Response suppression deficits in treatment-naïve first-episode patients with schizophrenia, psychotic bipolar disorder and psychotic major depression.

Margret S H Harris1, James L Reilly, Michael E Thase, Matcheri S Keshavan, John A Sweeney.   

Abstract

Recent evidence indicates common genetic, neurobiological, and psychopharmacological aspects of schizophrenia and psychotic affective disorders. Some similarities in neurocognitive deficits associated with these disorders have also been reported. We investigated performance on antisaccade and visually-guided saccade tasks in treatment-naïve first-episode psychosis patients (schizophrenia n=59, major depression n=15, bipolar disorder n=9), matched non-psychotic major depression patients (n=40), and matched healthy individuals (n=106). All psychosis groups displayed elevated antisaccade error rates relative to healthy individuals. Antisaccade latencies were elevated in schizophrenia, but no significant error rate or latency differences were observed among psychosis groups. For schizophrenia only, shorter visually guided saccade latencies were associated with higher antisaccade error rates. Schizophrenia was also the only group without a significant relationship between visually guided and antisaccade latencies. Reflexive saccades were unimpaired except in psychotic unipolar depression, where saccades were hypometric. As in schizophrenia, antisaccade abnormalities are present in affective psychoses, even early in the course of illness and prior to treatment. Disturbances in frontostriatal systems are believed to occur in both affective psychoses and schizophrenia, potentially causing some similar cognitive abnormalities across psychotic disorders. However, the distinct pattern of dysfunction in schizophrenia across oculomotor paradigms suggests possible unique causes of their observed oculomotor performance deficits.

Entities:  

Mesh:

Year:  2009        PMID: 19906441      PMCID: PMC2792232          DOI: 10.1016/j.psychres.2008.10.031

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  39 in total

1.  Linkage of a composite inhibitory phenotype to a chromosome 22q locus in eight Utah families.

Authors:  M Myles-Worsley; H Coon; J McDowell; C Brenner; M Hoff; B Lind; P Bennett; R Freedman; B Clementz; W Byerley
Journal:  Am J Med Genet       Date:  1999-10-15

Review 2.  Commentary: eye movement research with clinical populations.

Authors:  John A Sweeney; Deborah Levy; Margret S H Harris
Journal:  Prog Brain Res       Date:  2002       Impact factor: 2.453

3.  Saccadic eye movements, schizotypy, and the role of neuroticism.

Authors:  Ulrich Ettinger; Veena Kumari; Trevor J Crawford; Vanja Flak; Tonmoy Sharma; Robert E Davis; Philip J Corr
Journal:  Biol Psychol       Date:  2005-01       Impact factor: 3.251

4.  The association between antisaccade task and working memory task performance in schizophrenia and bipolar disorder.

Authors:  D C Gooding; K A Tallent
Journal:  J Nerv Ment Dis       Date:  2001-01       Impact factor: 2.254

Review 5.  Probing prefrontal function in schizophrenia with neuropsychological paradigms.

Authors:  T E Goldberg; D R Weinberger
Journal:  Schizophr Bull       Date:  1988       Impact factor: 9.306

6.  Neuropsychological and clinical correlates of antisaccade task performance in schizophrenia.

Authors:  D H Nieman; L J Bour; D H Linszen; J Goede; J H Koelman; B P Gersons; B W Ongerboer de Visser
Journal:  Neurology       Date:  2000-02-22       Impact factor: 9.910

7.  The regional cerebral blood flow changes in major depressive disorder with and without psychotic features.

Authors:  Ali Saffet Gonul; Mustafa Kula; Arzu Guler Bilgin; Ahmet Tutus; Aslan Oguz
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2004-09       Impact factor: 5.067

8.  Antisaccade performance is impaired in medically and psychiatrically healthy biological relatives of schizophrenia patients.

Authors:  Monica E Calkins; Clayton E Curtis; William G Iacono; William M Grove
Journal:  Schizophr Res       Date:  2004-11-01       Impact factor: 4.939

9.  Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder.

Authors:  Tsung-Ung W Woo; John P Walsh; Francine M Benes
Journal:  Arch Gen Psychiatry       Date:  2004-07

10.  Neuropsychological dysfunction in antipsychotic-naive first-episode unipolar psychotic depression.

Authors:  S Kristian Hill; Matcheri S Keshavan; Michael E Thase; John A Sweeney
Journal:  Am J Psychiatry       Date:  2004-06       Impact factor: 18.112

View more
  26 in total

Review 1.  Major depressive disorder is associated with broad impairments on neuropsychological measures of executive function: a meta-analysis and review.

Authors:  Hannah R Snyder
Journal:  Psychol Bull       Date:  2012-05-28       Impact factor: 17.737

2.  Facial emotion recognition in first-episode schizophrenia and bipolar disorder with psychosis.

Authors:  Alexander R Daros; Anthony C Ruocco; James L Reilly; Margret S H Harris; John A Sweeney
Journal:  Schizophr Res       Date:  2014-01-21       Impact factor: 4.939

3.  Behavioral response inhibition in psychotic disorders: diagnostic specificity, familiality and relation to generalized cognitive deficit.

Authors:  Lauren E Ethridge; Melanie Soilleux; Paul A Nakonezny; James L Reilly; S Kristian Hill; Richard S E Keefe; Elliot S Gershon; Godfrey D Pearlson; Carol A Tamminga; Matcheri S Keshavan; John A Sweeney
Journal:  Schizophr Res       Date:  2014-09-26       Impact factor: 4.939

4.  Alterations in intrinsic fronto-thalamo-parietal connectivity are associated with cognitive control deficits in psychotic disorders.

Authors:  Rebekka Lencer; Li Yao; James L Reilly; Sarah K Keedy; Jennifer E McDowell; Matcheri S Keshavan; Godfrey D Pearlson; Carol A Tamminga; Elliot S Gershon; Brett A Clementz; Su Lui; John A Sweeney
Journal:  Hum Brain Mapp       Date:  2018-09-10       Impact factor: 5.038

5.  The selective serotonin reuptake inhibitor, escitalopram, enhances inhibition of prepotent responding and spatial reversal learning.

Authors:  Holden D Brown; Dionisio A Amodeo; John A Sweeney; Michael E Ragozzino
Journal:  J Psychopharmacol       Date:  2012-01-04       Impact factor: 4.153

6.  Antisaccade and prosaccade eye movements in individuals clinically at risk for psychosis: comparison with first-episode schizophrenia and prediction of conversion.

Authors:  Luca Kleineidam; Ingo Frommann; Stephan Ruhrmann; Joachim Klosterkötter; Anke Brockhaus-Dumke; Wolfgang Wölwer; Wolfgang Gaebel; Wolfgang Maier; Michael Wagner; Ulrich Ettinger
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-01-11       Impact factor: 5.270

7.  Alterations in hippocampal connectivity across the psychosis dimension.

Authors:  Niyatee Samudra; Elena I Ivleva; Nicholas A Hubbard; Bart Rypma; John A Sweeney; Brett A Clementz; Matcheri S Keshavan; Godfrey D Pearlson; Carol A Tamminga
Journal:  Psychiatry Res       Date:  2015-06-16       Impact factor: 3.222

8.  A step towards non-invasive characterization of the human frontal eye fields of individual subjects.

Authors:  Andreas A Ioannides; Peter Bc Fenwick; Elina Pitri; Lichan Liu
Journal:  Nonlinear Biomed Phys       Date:  2010-06-03

9.  Interocular yoking in human saccades examined by mutual information analysis.

Authors:  Masaki Maruyama; Peter Bc Fenwick; Andreas A Ioannides
Journal:  Nonlinear Biomed Phys       Date:  2010-06-03

10.  Distinguishing patterns of impairment on inhibitory control and general cognitive ability among bipolar with and without psychosis, schizophrenia, and schizoaffective disorder.

Authors:  Milena Y Gotra; Scot K Hill; Elliot S Gershon; Carol A Tamminga; Elena I Ivleva; Godfrey D Pearlson; Matcheri S Keshavan; Brett A Clementz; Jennifer E McDowell; Peter F Buckley; John A Sweeney; Sarah K Keedy
Journal:  Schizophr Res       Date:  2020-07-14       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.